Li Ping, He Quanyong, Luo Chenqun, Qian Liyuan
Department of Cosmetic Surgery, The Third Xiangya Hospital, Central South University Changsha, Hunan, China.
Department of General Surgery, The Third Xiangya Hospital, Central South University Changsha, Hunan, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):660-4. eCollection 2015.
Accumulating evidence demonstrated a link of increased expression of Angiopoietin-2 (Ang-2) with invasive and metastatic phenotypes of various types of human cancers. However, until now, the serum level and its diagnostic and prognostic potential in breast cancer have not been investigated.
Enzyme-linked immunosorbent assays were used to measure the levels of Ang-2. Sensitivity, specificity and area under curve (AUC) for serum Ang-2 levels were determined using receiver operator characteristic (ROC) analysis. Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test. Prognostic relevance of each variable to overall survival (OS) and disease-free survival (DFS) were analyzed using the Cox regression model.
Serum expression of Ang-2 in patients with breast cancer was significantly higher than healthy control group (3171 ± 1024 vs. 1800 ± 874 pg/ml, P < 0.0001). ROC curve analysis showed that at the optimal cut-off (2558.5 pg/ml), serum level of Ang-2 had a sensitivity of 78.3% and a specificity of 77.0% for distinguishing breast cancer patients from healthy controls with an area under the curve (AUC) of 0.836 (P < 0.001, 95% confidence interval: 0.787-0.885). The 5-year OS of high Ang-2 expression group was significantly shorter than that of low Ang-2 expression group (55.9% vs. 80.3%; P = 0.018). Moreover, the 5-year DFS of high Ang-2 expression group was also significantly shorter than that of low Ang-2 expression group (46.0% vs. 68.7%; P = 0.029).
Our data indicate that serum Ang-2 level has potential value for early detection of breast cancer. Furthermore, Ang-2 has prognostic value in patients with breast cancer.
越来越多的证据表明，血管生成素-2（Ang-2）表达增加与多种类型人类癌症的侵袭性和转移表型有关。然而，迄今为止，尚未对乳腺癌患者的血清水平及其诊断和预后潜力进行研究。
采用酶联免疫吸附测定法测量Ang-2水平。使用受试者工作特征（ROC）分析确定血清Ang-2水平的敏感性、特异性和曲线下面积（AUC）。采用Kaplan-Meier法绘制生存曲线，并使用对数秩检验分析生存率差异。使用Cox回归模型分析每个变量与总生存期（OS）和无病生存期（DFS）的预后相关性。
乳腺癌患者血清中Ang-2的表达明显高于健康对照组（3171±1024 vs. 1800±874 pg/ml，P<0.0001）。ROC曲线分析表明，在最佳临界值（2558.5 pg/ml）时，血清Ang-2水平区分乳腺癌患者与健康对照的敏感性为78.3%，特异性为77.0%，曲线下面积（AUC）为0.836（P<0.001，95%置信区间：0.787-0.885）。高Ang-2表达组的5年总生存期明显短于低Ang-2表达组（55.9% vs. 80.3%；P=0.018）。此外，高Ang-2表达组的5年无病生存期也明显短于低Ang-2表达组（46.0% vs. 68.7%；P=0.029）。
我们的数据表明，血清Ang-2水平对乳腺癌的早期检测具有潜在价值。此外，Ang-2对乳腺癌患者具有预后价值。
